This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/2/2026
Good morning, and welcome to the Axiom Therapeutics third quarter 2026 earnings conference call. My name is Kevin. I'll be your operator for today's call. At this time, all participants are in listening-only mode. Later, we'll conduct a question-and-answer session. Instructions will be given at that time. Please note, this call is being recorded. I will now turn the call over to Ashley Dong, Senior Director of Investor Relations. Ashley, please go ahead.
Thank you. Good morning, everyone. Welcome to Axiom's third quarter 2026 earnings conference call. Joining me today are Dr. Herriot Tabuteau, Chief Executive Officer, Nick Pizzie, Chief Financial Officer, and Ari Maizel, Chief Commercial Officer, who will begin with prepared remarks. Mark Jacobson, our Chief Operating Officer, and Hunter Murdock, our General Counsel, will also be available for Q&A. Before we begin, I encourage everyone to visit the Investors section of our website to find the press release and presentation for today's call. Please note that today's discussion includes forward-looking statements regarding our financial performance, commercial strategy, and operational plans, including research, development, and regulatory activities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Please refer to our SEC filings, including our quarterly and annual reports, for a description of these and other risks. You are cautioned not to rely on these forward-looking statements, which are made only as of today, and the company disclaims any obligation to update such statements. And with that, I'll hand it over to Herriot.
Thank you, Ashley, and good morning, everyone. Axiom delivered another robust quarter across our business. driven by continued commercial progress and advancements in our industry-leading neuroscience pipeline. Our commercial portfolio generated $260 million in total revenue in the quarter, representing growth of 52% year-over-year, surpassing a $1 billion annual run rate. We expect sustained momentum for availability driven by strong underlying demand growth in major depressive disorder and continued acceleration of new patient initiations in Alzheimer's disease agitation. The nosing continues to show persistent and steady growth. And for Sembravo, our expanded sales team is driving important trial and adoption. Nick will discuss our financials for the quarter, followed by Ari, who will comment on our commercial business. In parallel with the commercial portfolio, Our industry-leading neuroscience pipeline comprises 10 development programs, including significant label expansion opportunities for Velody and Synose, as well as novel product candidates with potential first-in-class and best-in-class profiles across areas of high unmet need in brain health. I will review our recent pipeline progress later in the call. Overall, our commercial portfolio is growing. and our industry-leading R&D portfolio is well positioned to potentially deliver multiple ways of innovation to patients. I will now turn the call over to Nick to review our financials.
You're reading a preview of the AXSM Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing